Anti-angiotensin Therapy: New Perspectives

Cardiology Clinics

Volumn 25, Issue 4, 2007, Pages 573-580

  Ramasubbu, Kumudha ^a   Mann, Douglas L ^b   Deswal, Anita ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; SPIRONOLACTONE; VALSARTAN;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; HEART FAILURE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; FUMARATES; HEART FAILURE; HUMANS; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 36549019487     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.09.003     Document Type: Review

References (35)

1. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 355 (2000) 637-645
2. Jorde U.P., Ennezat P.V., Lisker J., et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101 (2000) 844-846
3. Kawamura M., Imanashi M., Matsushima Y., et al. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol 19 (1992) 547-553
4. de Gasparo M., and Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?. Pharmacol Toxicol 82 (1998) 257-271
5. Wolny A., Clozel J.-P., Rein J., et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 80 (1997) 219-227
6. McConnaughey M.M., McConnaughey J.S., and Ingenito A.J. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 39 (1999) 547-559
7. Petrie M.C., Padmanabhan N., McDonald J.E., et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37 (2001) 1056-1061
8. Dzau V.J. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 7 (1989) 933-936
9. Okunishi H., Oka Y., Shiota N., et al. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 62 (1993) 207-210
10. Liao Y., and Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 11 Suppl F (1995) 13F-19F
11. Urata H., Healy B., Stewart R.W., et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66 (1990) 883-890
12. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 42 (1992) 1020-1029
13. Israili Z.H., and Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117 (1992) 234-242
14. Rump L.C., Oberhauser V., Schwertfeger E., et al. Experimental evidence to support ELITE. Lancet 351 (1998) 644-645
15. Pitt B., Segal R., Martinez F.A., et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349 (1997) 747-752
16. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. [In Process Citation]. Lancet 355 (2000) 1582-1587
17. Berlowitz M.S., Latif F., Hankins S.R., et al. Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers. J Cardiovasc Pharmacol 37 (2001) 692-696
18. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
20. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. [In Process Citation]. Lancet 355 (2000) 1575-1581
21. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
22. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
23. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
24. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
25. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy 10. N Engl J Med 345 (2001) 861-869
26. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
27. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
28. VALIANT: Implications and explanations 12931. HeartWire News. Available at: http://www.theheart.org/viewEntityDispatcherAction.do?primaryKey=470958. Accessed May 2007.
29. Messerli F.H., and Re R.N. Do we need yet another blocker of the renin-angiotensin system?. J Am Coll Cardiol 49 (2007) 1164-1165
30. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
31. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators. Circulation 100 (1999) 1056-1064
32. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
33. Oh B.H., Mitchell J., Herron J.R., et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49 (2007) 1157-1163
34. O'Brien E., Barton J., Nussberger J., et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49 (2007) 276-284
35. Mann D.L., Deswal A., Bozkurt B., et al. New therapeutics for chronic heart failure. Annu Rev Med 53 (2002) 59-74